Research during the last two decades has firmly established that follicle-stimulating hormone (FSH), like other glycoproteins, is not a unique protein, but rather a family of heterogeneous isoforms of varying immunologic and bioactive potencies. Such mixes of isoforms are found within the pituitary, resulting from differential promoter action, alternative splicing, induction of point mutations during biosynthesis, or posttranslational changes, including carbohydrate incorporation prior to or during granule formation within the gonadotrope. Upon secretion, these molecular variations determine tertiary structure and metabolic clearance. Molecules lacking sialic acid residues (relatively less acidic) have shorter half-lives within the circulation, Inese Z. Beitins and Vasantha Padmanabhan are at the Division of Pediatric Endocrinology at the University of Michigan, Ann Arbor, MI 48109-0718, USA. yet bind avidly to the target tissue receptors, whereas those with full carbohydrate complements, including sialic acid, circulate longer, but bind less well in vitro. Therefore, it is the proportion of the various isofotms that reach the target cell receptors that influences not only receptor binding, but also signal transduction, in a variety of measurable biologic end points.
A biologic potency can be defined as the equivalent response obtained by the testing material to a known dose of a purified reference preparation upon a measurable biologic response within an organism, organ, or cellular system in vitro. Various postreceptor-binding end points have been used for FSH assays. In in vivo bioassays, hypophysectomized mice or immature rats were treated with pituitary or urinary extracts, which had been extensively purified chemically and concentrated (serum could not be used). Each assay required a large number of animals, whose overall health and weight could be detrimentally affected by remaining toxins or foreign proteins within the test materials, thus leading to poor reproducibility of results. Though the assays incorporated metabolic clearance, they were relatively insensitive compared with immunoassays. With immunoassay development, standards and antibodies were preferentially selected that would provide the desired sensitivity and exhibit parallel responses to the test materials. It became evident early, however, that comparisons of in vivo bioassay responses of extracted rat pituitary FSH to immunoassay potencies did not provide consistent bioactive to immunoreactive (B-I) ratios. Furthermore, steroid treatment of castrated rats altered the B-I ratio of FSH as well as its clearance (Bogdanove et al. 1973) . These studies led to the hypothesis that both G&I-I stimulation and steroid modulation altered not only the quantity but also the quality of the hormone (Chappel et al. 1983) .
These initial observations were extended to other animal species, such as the hamster (Chappel et al. 1983) . A series of experiments studying FSH isofoxm distribution patterns following chromatofocusing and measuring hormonal potencies by means of receptor binding, in vitro bioassay and immunoassay methods confirmed that GnRH stimulation and sex steroid modulation, as in the estrous cycle or throughout puberty, induced shifts within the FSH isoform distribution patterns. Shifts from the acidic to relatively more basic isoforms also resulted from neuraminidase treatment, confirming the importance of the presence of sialic acid upon the p1 of the FSH molecule.
Though sensitive and precise in vitro bioassays utilizing rat interstitial cell testosterone production (RICT) had been validated and widely used for measurements of dynamic changes in the B-I ratios of luteinizing hormone (LH) in a variety of physiologic and pathophysiologic conditions (Dufau and Veldhuis 1987) the development of similar in vitro bioassays suitable for measurement of FSH in unextracted serum lagged behind. In rat granulosa cells, aromatase could be reliably induced by FSH standards, yet the addition of serum to the in vitro system depressed the biologic response and led to nonparallelism. This problem was overcome by treating serum with 12% polyethylene glycol (PEG) (Jia and Hsueh 1985) . We, on the other hand, optimized the conditions of the rat Sertoli cell aromatase induction assay first described by Van Damme et al. (1979) . By improving the sensitivity severalfold, we are now able to reliably determine FSH in unextracted serum (Padmanabhan et al. 1987) and urine.
Building upon the experience with bioassayed (B)-LH and its comparisons with immunologic potencies, which addressed sex differences, regulation of secretion by GnRH and modulation by sex steroids, plasma clearance, and responses to GnRH agonists and antagonists, we now describe similar experiences with the newly validated in vitro FSH bioassays. Because these in vitro bioassays, unlike the immunoassays, have only limited species specificity, they can be utilized in animal models either to confirm regulatory mechanisms impossible to study in the human or chart new territory in reproductive endocrinology in a variety of species where FSH measurements were previously not possible.
Within our own work, we have tested the overall hypothesis, which was first proposed by Chappel et al. (1983) but, owing to increased serum I-FSH levels, lower mean serum FSH B-I ratios (1.4 i: 0.2 and I.5 + 0.5, respectively) (Tenover et al. 1987; Wang et al. 1987) . Men with severe oligospermia, on the other hand, had elevated serum B-and I-FSH concentrations, with a B-I ratio of 1.7 f 0.3. Elderly men with prostatic carcinoma had mean serum B-FSH concentrations of 19.7 * 4.1 ID/L, with a B-I ratio of 1.7 k 0.2 (Huhtaniemi et al. 1988) . Treatment with a GnRH analogue decreased serum I-FSH concentrations to a greater extent than serum B-FSH concentrations, with a resulting B-I ratio of 6.7 f 0.8 in 2-3 weeks of treatment from cross-sectional studies in men and women. B-FSH was not detected in the sera from hypophysectomized patients or women treated with oral contraceptives. With both assays, serum B-FSH values were lowest in men, followed by women during the luteal and follicular phases of their menstrual cycles. Sera from postmenopausal women and women with premature ovarian failure contained the highest B-FSH concentrations, which exceeded values observed during the midcycle of menstruating women.
?? Serum B-FSH Levels and FSH B-I Ratios in Men
With the GAB assay, cross-sectional studies have been performed comparing serum B-FSH concentrations and B-I ratios in normal young men, elderly men, and men with idiopathic azoospermia, oligospermia, and prostatic cancer. The effects of GnRH agonist and antagoand a gradual decline to pretreatment B-I ratio levels by 6 months. Orchidectomy at this point caused an initial increase in 2 weeks to a mean serum FSH B-I ratio of 6.6-6.8, with a decline toward pretreatment ratios during the next 3 months. In normal men treated with GnRH agonists, with or without testosterone enanthate, the serum FSH B-I ratios remained unchanged (Pavlou et al. 1988) . Five men treated with a potent GnRH antagonist clearly demonstrated that serum B-FSH levels were suppressed to a greater extent than were serum I-FSH levels (Dahl et al. 1986 ). These effects led to a dramatic lowering of the serum FSH B-I ratio. (Jia et al. 1986; Fauser et al. 1989 ) and the Sertoli cell assay (Padmanabhan et al. 1988b; Beitins et al. 1990) . With the GABA, the serum B-FSH concentrations paralleled those of serum I-FSH, with no change in the FSH B-I ratio throughout all phases of the menstrual cycle. The FSH B-I ratio ranged from 1.4 to 3.4, with a mean of 2.5. Urinary B-FSH levels, obtained in daily first morning void samples, however, exhibited marked elevations in urinary B-FSH concentrations, which coincided with the LH peak (Dahl et al. 1987 ). There was a highly significant correlation between serum and urinary B-FSH. Infusion of an antagonist of GnRH at 30 ng/kg h in women during the midfollicular phase suppressed B-FSH levels by 64%, but I-FSH only by 29%. When the GnRH antagonist was given subcutaneously at a higher dose of 80 ug/kg twice daily for 3 days during the midfollicular phase, the B-FSH response was biphasic, with a maximal decrease until term, but 6 weeks postpartum on the second day, returning to basal B-FSH levels were low and did not levels by the third (Kessel et al. 1988) .
increase with GnRH stimulation. Having used the Sertoli cell assay, Padmanabhan et al. (1988b) reported that women during the menstrual cycle had significantly higher B-FSH concentrations during the midcycle than the follicular phase. The serum FSH B-I ratio was the highest during this phase of the menstrual cycle and the lowest during the luteal phase. These changes in serum B-FSH reflected shifts in the distribution of FSH isoforms from the acidic to a relatively basic p1 (with higher B-I ratios) upon chromatofocusing. These results were compatible with the hypothesis that less sialylated, shorter-lived FSH isoforms circulated during the midcycle period and may participate in dynamic functions such as ovulation. The relative shift of the FSH isoform biosynthesis and secretion could be due to either increased GnRH pulse frequency or the rising sex steroid values. These potent FSH isoforms could participate in the induction of plasminogen activator, activating plasmin, finally leading to the breakdown of collagen fibers present in the tissues of the ovulating follicles (Hsueh et al. 1989 ).
?? Serum B-FSH Concentrations During Development and Puberty
In human fetuses, who have had chordocentesis for medical indications but were found to be normal, serum B-FSH concentrations were higher in girls than boys at 20-25 weeks of gestation, but declined and were no longer significantly different between the sexes at 35 and 40 weeks of gestation (unpublished data). In samples drawn simultaneously from the mother and by chordocentesis, the maternal B-FSH levels were -3 times higher than in the fetus. The B-FSH serum concentrations during fetal life near term were -10 times higher than those during pubertal development in boys and girls.
During the menstrual cycle studies, several women had become pregnant. Serum B-FSH levels, in contrast to I-FSH levels, increased significantly from postovulation day 7 to the end of the menstrual cycle study period. The serum FSH B-I ratio increased from 2.5 on the LH peak day to 70 by day 15 after the LH peak day. In another study, blood samples had been obtained every 10 min for 10 h on days 10,20, and 27 after the LH peak in a pregnant woman. The serum B-FSH concentrations appeared pulsatile and the FSH B-I ratio was likewise elevated. This FSH-like bioactive material was not due to cross reaction with hCG, j3 subunit, a-hCG, a-fetoprotein, or human placental lactogen. Removal of steroids by charcoal extraction did not alter the final results. FSH-like activity was present in the media from placental incubates, with an FSH B-I ratio of 47.1 (Padmanabhan et al. 1989a ). FSH-like bioactive material was also secreted by choriocarcinoma cells in culture. The increase of B-FSH in pregnancy serum was confirmed by FSH isoform distribution patterns. There was a progressive increase in serum B-FSH-like activity From cross-sectional as well as longitudinal studies of bioactive gonadotropin concentrations throughout puberty, though B-LH levels rose progressively through each stage of puberty, B-FSH serum concentrations did not change significantly (Reiter 1982; Beitins et al. 1990 ). The serum B-FSH concentrations were as high during the prepubertal period as during later stages of puberty when both boys and girls had matured and sex steroid concentrations were significantly increased. Serum I-FSH concentrations were significantly higher during puberty in girls than boys, with the resulting serum FSH B-I ratio significantly lower in girls than boys. Serum B-FSH levels during puberty were not significantly different from those of men and women during the follicular phase of the menstrual cycle, but were lower than during the periovulatory period. Similar findings have been reported in girls with precocious puberty (Wang et al. 1990 ). Basal serum B-FSH levels were not significantly different in patients with precocious puberty, premature thelarche, or prepubertal controls. After 12 months of GnRH agonist therapy, both I-FSH and B-FSH concentrations were suppressed in patients with precocity. The serum FSH B-I ratio was not changed. In 12 volunteers from ages 5-12 years, however, overnight urinary excretion of B-FSH, expressed per milligram of creatinine, revealed a gradual increase from childhood to pre-and postmenarchalperiod (Fauseret al. 1989 ). The number of subjects per group was small (n = 3) and the differences in urinary concentrations increased less than twofold.
?? Regulation of B-FSH Secretion

Role of GnRH
From the preceding studies, it is apparent that GnRH and GnRH agonists and antagonists influence B-and I-FSH secretion and potency. This was further confirmed by administering small pulses of GnRI-I (0.025 ug/kg) intravenously at hourly intervals for 3-5 days to boys with idiopathic hypogonadotropic hypogonadism (Padmanabhan et al. 1988a ). Serum B-FSH concentrations increased significantly after 9 1% of the GnRH doses, even at times when there were no increases in serum I-FSH, I-LH, or sex steroid concentrations. The serum B-FSH responses occurred consistently within 20 min after the GnRH administration, but the B-FSH levels had returned to baseline by 60 min, indicating rapid clearance of the newly secreted B-FSH.
In midpubertal boys who had blood withdrawn every 10 min from 2000 to 0800 h, B-FSH was secreted in clearly discernible pulses before, during, and after the onset of sleep (Hassing et al. 1990 ). In association with the increased frequency and amplitude of I-LH pulses, there was a minimal, but significant, increase in mean B-FSH levels 0, = 0.046), pulse frequency (p = 0.045), but not B-FSH pulse amplitude. When testosterone was infused at the rate of the adult male production rate, the mean serum I-LH rise and nocturnal increase in LH pulse frequency were abolished without an effect on B-FSH pulsatility.
To dissect the relative contribution of GnRH versus steroids further, nutritionally growth-retarded ovariectomized lambs were studied during nutritional repletion (Padmanabhan et al. 1989b) . In this animal model, LH secretory pulses were utilized as an index of endogenous GnRH secretion. During the period of nutritional restriction, I-LH and I-FSH levels were low and relatively apulsatile in serial blood samples obtained every I2 min for 4 h. In contrast, serum B-FSH showed a pulsatile secretory pattern that became even more apparent with nutritional repletion. In contrast to increasing I-LH pulse frequency, FSH pulse frequency remained stable, whereas FSH pulse amplitude increased.
Serum B-FSH pulse amplitudes were 57 f 7% greater than I-FSH pulses. The asynchronous occurrence of FSH pulses in the absence of I-LH pulses led us to speculate that FSH may be more sensitive to small changes in GnRH secretion than I-LH or that a hypothalamic releasing factor specific for FSH may be present.
Effect of Steroids on B-FSH Secretion
In addition to the study with the acute testosterone infusion in midpubertal boys described above, the effects of acute (24 h) infusions and long-term steady-state infusions of dihydrotestosterone (DHT) and estradiol (E,) in normal men have been performed. Men infused with E, to elevate their mean serum E, to twice their endogenous E, levels for 24 h did not have a significant change in their mean serum B-FSH levels. Likewise, when DHT or E, was infused for a total of 5'12 days and blood withdrawn every 10 min for the last 28 h, the mean serum B-FSH concentrations in pooled samples were not significantly different whether measured with the Sertoli cell aromatase induction or GABA (Urban et al. 1990 ). Therefore, it appeared that neither T, DHT, or E, significantly altered mean B-FSH serum concentrations in midpubertal boys and men.
In women with gonadal dysgenesis treated with estrogenic steroids for 21 days, there was an initial parallel decline in the B-and I-FSH levels for about the first 14 days with a stable serum FSH B-I ratio. During week 3, however, I-FSH levels continued to decline while serum B-FSH levels remained stable, leading to a significant increase in the serum FSH B-I ratio (Padmanabhan et al. 1988b ). This increase in the FSH B-I ratio was similar to that obsetved during the periovulatory period of the menstrual cycle, when both GnRH pulse frequency and amplitude as well as serum E, levels were increasing.
In women with polycystic ovary syndrome (PCOS), endogenous serum androgens are elevated. Irrespective of whether the patients had elevated baseline and post-GnRH stimulation I-LH levels or whether they were relatively normal (group II), mean serum B-FSH concentrations were higher than serum I-FSH concentrations and similar to levels found in normal women during the follicular phase (unpublished data). When E, and progesterone were replaced at luteal concentrations for 20 days, mean serum I-FSH concentrations decreased significantly (2.3 + 0.2 to 0.6 + 0.1 ug/L), while mean serum B-FSH concentrations remained stable (3.4 +0.2 vs 3.1 + 0.3 l.rg/L.). The resulting serum FSH B-I ratio increased from 1.6 fO.l to 7.0+ 2.6 07 < 0.01). The mean serum B-FSH concentrations in the presence of luteal phase levels of E, and progesterone were significantly higher than during the spontaneous luteal phases (1.4 f 0.2 ug/L). These results indicated that serum B-FSH levels in PCOS were slightly higher than in normal controls but did not suppress with luteal phase E, and P administration in a manner similar to serum I-FSH.
The low serum B-FSH levels during the spontaneous luteal phase were probably related to secretions from the corpus luteum itself.
?? FSH Isoform Distribution Patterns and FSH Clearance in the Human
FSH isoform distribution patterns are difficult to obtain from unaltered human tissues and biologic fluids. Pituitaries obtained postmortem are subject to autolysis and those removed because of tumors may not synthesize normal hormonal isoforms. Plasma concentrations of FSH are relatively low. Nevertheless, FSH isoform distribution patterns from FSH-secreting tumors confirmed animal studies and revealed that the highest FSH B-I ratios were present in the less acidic fractions of the chromatofocused eluates (Padmanabhan et al. 1988b) . FSH extracted from pituitaries was qualitatively different in young women from FSH derived from men and elderly women (Wide and Hobson 1983) . FSH isoform distribution patterns from chromatofocused serum revealed an increase in the relatively less acidic FSH isoforms during the periovulatory period as well as following chronic estrogenic therapy in women with gonada1 dysgenesis. Therefore, during high estrogenic states, circulating FSH isoforms are less acidic (less sialic acid) and have a shorter circulation time, but retain binding to target tissue receptors. Conversely, during states of low estro-genie stimulation, such as the follicular phase of the menstrual cycle (Padmanabhan et al. 1988b ), men, postmenopausal women, and castrated men (Wide and Hobson 1983) , the charge of the FSH is relatively more acidic. Treatment with neuraminidase eliminated the FSH charge differences (Wide 1986) . GnRH stimulation in patients with Turner's syndrome likewise induced the appearance of less negatively charged FSH isoforms in electrophoretic mobility studies (Wide and AlbertssonWiklund 1990) . Finally, infusion of a GnRH antagonist into hypogonadal women increased basic FSH isoforms, as determined by chromatofocusing (Dahl et al. 1988a ). These isoforms bound to granulosa cell FSH receptors, but were devoid of biologic activity and, in fact, inhibited FSH action, In addition to the differential binding to FSH receptors and induction of biologic responsiveness, different FSH isoforms are cleared from the circulation at different rates. FSH extracted from pituitaries of young women was cleared from the circulation of mice at a faster rate than FSH from men or elderly women (Wide and Wide 1984) . Studies combining studies of molecular mobility on electrophoresis with metabolic clearance rate determined that the less negatively charged FSH isoforms are cleared more rapidly (Wide 1986) . Therefore, the charge (PI or sialic acid content) regulates the survival of FSH within the circulation.
From the studies utilizing in vitro FSH bioassays, the disappearance of newly secreted FSH in response to GnRH in patients with idiopathic hypogonadotropic hypogonadism is -60 min (Padmanabhan et al. 1988a) . This is in contrast to the determinations based on I-FSH measurements after hypophysectomy or bolus injection, where the plasma half-life was stated to be 240 min. We have recently calculated the half-life of purified human FSH (Metrodin) during continuous steady-state infusions in hypogonadotropic men. The FSH half-life for this material was 3.2 h by in vitro bioassay for a one-component fit and 0.9 h (fast) and 8.3 h (slow) for a twocomponent fit (unpublished data). The half-life of endogenous and exogenous infused FSH appears to be more rapid when estimated by in vitro bioassay than by immunoassays.
?? Urinary B-FSH in Various Species
In vitro FSH bioassays can be utilized in a variety of animal species. We have validated the assay for the measurement of B-FSH in sex-a of sheep (Padmanabhan et al. 1989b) . With the GABA for unextracted small quantities of urine, urinary B-FSH levels have been measured in rats during puberty (Dahl et al. 1988b), lowland gorillas (Dahl and Hsueh 1987) , giant panda (Montfort et al. 1989) , and killer whales (Walker et al. 1988) . In all of these animal species, urinary estimates integrated pulsatile serum patterns (if they existed) and reduced the stress of handling and venipuncture. Urinary B-FSH was measured in male and female rats from birth to 40 days of age. Detectable urinary B-FSH levels were present during the neonatal period and throughout puberty. The urinary B-FSH profiles were highly correlated with serum B-FSH (r = 0.93). Urinary concentrations, however, were 50 times higher than in serum. In the lowland gorilla, a midcycle B-FSH surge was detected. Two peaks of FSH were present during the follicular phase in the gorilla as well as the giant panda. The latter likewise had a urinary periovulatory FSH peak. A similar bimodal urinary B-FSH pattern was found in the killer whale. This method of measurement therefore provides useful information regarding reproductive hormones, their regulation, and their reproductive cyclicity in endangered species and marine mammals. This information can be skillfully utilized in the management and breeding programs of these animals.
The reasons for the greater urinary than serum B-FSH concentrations (loofold during the menstrual cycle in women and SO-fold during maturation in the rat) are not known (Dahl et al. 1988b ). Customarily, in human studies, to satisfy the principle of using the standard derived from the same source as the test material, pituitary FSH standards have been used for serum FSH determinations and urinary FSH for urinary FSH estimates. Also, the methods of extraction for the Steelman-Pohley in vivo bioassay and immunoassay are different. Nevertheless, with all these reservations, we have found the urinary FSH B-I ratio to be 1.16 f 0.11 in postmenopausal women (Beitins et al. 1980 ). We have not yet made similar comparisons using the in vitro bioassay for FSH. Much additional work regarding FSH clearance needs to be performed to determine whether the urine contains a large proportion of the desialylated rapidly cleared FSH isoforms that still retain in vitro bioactivity. Thus, during puberty, when the urinary B-FSH levels have been shown to increase, but the serum B-FSH concentrations remain stable, urinary B-FSH determinations may shed more light upon the types of FSH isoforms that circulate and are excreted than the arduous task of performing chromatofocusing studies in sera with low values of B-FSH.
?? summary The availability of the in vitro FSH bioassay enabled, for the first time, the beginning of studies regarding the neuroendocrine regulation of FSH biosynthesis and secretion according to models widely utilized for LH (I-LH pulse characteristics and B-LH circulatory patterns). The ability to determine B-FSH pulses in serum has revealed that LH and FSH are differentially regulated and released in animals and man. In addition, studies with GnRH agonists and antagonists reveal differential regulation of B and I-LH secretion. During pregnancy, likewise, high circulating levels of B-FSH-like activity with low immunoreactivity are present. Chromatofocusing patterns of serum have confirmed that changes in the FSH B-I ratio are associated with shifts in the FSH isoform patterns. Estrogenic stimulation (midcycle, therapy) increases serum FSH B-I ratio in women, but not men, and is associated with an increase in the relatively less acidic FSH isoforms. Gonadal peptides such as inhibin in both sexes may modulate B-FSH secretion. Therefore, the overall regulation of gonadotropin synthesis, release, circulation time, receptor binding, and signal transduction is regulated at the pituitary gonadotrope. Small GnRH signals (in frequent and/or low amplitude) appear to promote FSH synthesis and release pteferentially until the signal has achieved the magnitude required for LH secretion. Then, with further maturation, gonadal peptides modulate FSH secretion, resulting in relatively stable mean FSH values while LH secretion is augmented. Sex steroids, on the other hand, modulate LH secretion to a greater extent than FSH. -hFSH-I-3) . By utilizing this methodology, large quantities of purified bioactive FSH can be made to be used as standards in assays, as well as physiologic and future clinical studies. In addition, by making single aminoacid substitutions in crucial points within the FSH sequence, alterations in glycosylation and tertiary structure can be induced. These mutants provide unparalleled opportunities for structure-function studies. Once the true importance and role of the various FSH isoforms is determined, it will be possible to design FSH isoforms for desired functions: sialylated, long-lived for growth and maintenance of reproductive organs; desialylated, short-lived for acute dynamic events, such as ovulation: and antagonistic FSH isoforms for potential use in contraception. 
